Low-Dose Drug Combo Safe in Kids with HIV (CME/CE)

Low-Dose Drug Combo Safe in Kids with HIV (CME/CE)
A low-dose treatment regimen with lopinavir/ritonavir antiretroviral therapy appears to have similar efficacy with fewer adverse events than standard dosing in HIV-infected children, researchers said here.

In the intention-to-treat analysis, 89 of 101 children (88.1%) on the low-dose regimen achieved undetectable viral loads using the 50 copies/ml assay (P
=0.38) compared with 90 of 98 children treated with the standard dose of lopinavir/ritonavir (Kaletra), said Thanyawee Puthanakit, MD, from Chulalongkorn University in Bangkok, and colleagues.
"This study demonstrated non-inferiority in virologic efficacy of low dose compared to standard dose lopinavir/ritonavir tablets as maintenance therapy," she reported at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.